Open an account

Embecta

EMBC · NASDAQ

$6.42+$0.21 (+3.38%)TodayMarket closed ·
Prev close $6.21

About EMBC

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. The company is headquartered in Parsippany, New Jersey and currently employs 1,850 full-time employees. The company went IPO on 2022-03-21. The firm has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. The company sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. The company also sells safety insulin syringes. The company distributes its products through a variety of channels, including retail, hospitals and pharmacies.

Employees
1,850
Headquarters
Parsippany, New Jersey
Listed
Mar 21, 2022
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
embecta.com

EMBC key statistics

Market cap
363.75M
Price-earnings ratio
4.22
Dividend yield
7.48%
Average volume
926.49K
Volume
746.03K
Open price
$6.29
High today
$6.52
Low today
$6.21
52 Week high
$14.91
52 Week low
$2.77

Embecta (EMBC) at a glance

Embecta (EMBC) last traded at $6.42, with a market cap of 363.75M, a price-to-earnings ratio of 4.22 and a dividend yield of 7.48%.

Today the stock has traded between $6.21 and $6.52. The current price is 3.5% above the day's low and 1.5% below its high.

Volume so far is 746.03K shares, in line with the average of 926.49K shares a day.

Over the past year Embecta has ranged from $2.77 to $14.91, and now sits 30% of the way up that range.

Embecta met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY26 it reported $0.56 per share against an estimate of $0.2703.

The average analyst price target is $10.20, 58.9% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 3 analyst ratings say Buy
  • Buy0.0%
  • Hold66.7%
  • Sell33.3%
Price target · 5 analystsAvg $10.20
Low
$3.03
Now
$6.42
High
$23.10

EMBC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 41.4% on average.

  1. Q4 FY24: reported $0.45 per share against an estimate of $0.3692
  2. Q1 FY25: reported $0.65 per share against an estimate of $0.4514
  3. Q2 FY25: reported $0.70 per share against an estimate of $0.5386
  4. Q3 FY25: reported $1.12 per share against an estimate of $0.7905
  5. Q4 FY25: reported $0.50 per share against an estimate of $0.5474
  6. Q1 FY26: reported $0.71 per share against an estimate of $0.6834
  7. Q2 FY26: reported $0.27 per share against an estimate of $0.4259
  8. Q3 FY26: reported $0.56 per share against an estimate of $0.2703

EMBC news

  • Press releasePRNewswire

    EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop

  • Press releaseBusiness Wire

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

  • Press releasePRNewswire

    EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

  • Press releaseGlobe Newswire

    EMBC Court News: Embecta Securities Fraud Class Action Filed After Insulin Pen Issues and 57% Stock Drop – Contact BFA Law Before August 17

  • Press releasePRNewswire

    Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC

  • Press releasePRNewswire

    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

  • Press releaseGlobe Newswire

    Embecta Corp. (EMBC) Notice of August 17, 2026 Deadline in Class Action Lawsuit – Hagens Berman

  • Press releasePRNewswire

    Embecta Corp. (EMBC) Investors: August 17, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman

Similar companies

Companies in the same industry as Embecta

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.